NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Ethema
Health Corporation (the “Company”) was incorporated under the laws of the state of Colorado, USA, on April 1, 1993. Effective
April 4, 2017, the Company changed its name to Ethema Health Corporation and prior to that, on May 2012, the Company had changed its
name to Greenstone Healthcare Corporation from Nova Natural Resources Corporation. As of December 31, 2017, the Company owned 100% of
the outstanding shares of Greenstone Clinic Muskoka Inc., incorporated in 2010 under the laws of the Province of Ontario, Canada; Cranberry
Cove Holdings Ltd., incorporated on January 9, 2004 under the laws of the Province of Ontario, Canada; Addiction Recovery Institute of
America (“ARIA”) (formerly Seastone Delray Healthcare, LLC), incorporated on May 17, 2016 under the laws of Florida, USA;
and Delray Andrews RE, LLC, incorporated on May 17, 2016 under the laws of Florida, USA.
During
December 2016, the Company obtained a license to operate and provide addiction treatment healthcare services in Florida, USA. The company
commenced operations under this license with effect from January 2017.
On
February 14, 2017, the Company completed a series of transactions (referred to collectively as the “Restructuring Transactions”),
including a Share Purchase Agreement (the “SPA”) whereby the Company acquired 100% of the stock of CCH, which holds the real
estate on which the Company previously operated a rehabilitation clinic (“the Canadian Rehab Clinic”). The Company entered
into an Asset Purchase Agreement (the “APA”) and lease (the “Lease”) whereby the Company sold all of the Canadian
Rehab Clinic business assets and leased the real estate to the buyer. Simultaneously with this transaction, the Company entered into
a Real Estate Purchase agreement and Asset Purchase Agreement whereby the Company purchased the real estate and business assets of Seastone
Delray (the “Florida Purchase”).
The
Share Purchase Agreement
Under
the SPA, the Company acquired 100% of the stock of CCH from Leon Developments Ltd.
(“Leon Developments”), a company wholly owned by Shawn E. Leon, who is the President, CEO, and CFO of the Company (“Mr.
Leon”). CCH owns the real estate on which the Canadian Rehab Clinic is located. The total consideration paid by the Company was
CDN$3,517,062, including the assumption of certain liabilities of CCH, which was funded by the assignment to Leon Developments of certain
indebtedness owing to the Company in the amount of CDN$659,918, and the issuance of 60,000,000 shares of the Company’s common stock
to Leon Developments, valued at US$0.0364 per share.
The
Asset Purchase Agreement and Lease
Under
the APA, the assets of the Canadian Rehab Clinic were sold by the Company, through its subsidiary, Greenstone Clinic Muskoka Inc. (“Muskoka”),
to Canadian Addiction Residential Treatment LP (the “Purchaser”), for a total consideration of CDN$10,000,000. The proceeds
of the Muskoka clinic asset sale were used to pay down certain tax debts and operational costs of the Company and to fund the Florida
Purchase, mentioned below.
Through
the APA, substantially all of the assets of the Canadian Rehab Clinic were sold, leaving Ethema with only the underlying clinic real
estate, which the Company, through its newly acquired subsidiary, CCH, concurrently leased to the Purchaser. The Lease is a triple net
lease and provides for a five (5) year primary term with three (3) five-year renewal options, annual base rent for the first year at
CDN$420,000 with annual increases, an option to tenant to purchase the leased premises and certain first refusal rights.
The
Florida Purchase
Immediately
after closing on the sale of the assets of the Canadian Rehab Clinic, the Company closed on the acquisition of the real estate assets
of Seastone Delray pursuant to certain real estate and asset purchase agreements The purchase price for the Seastone assets was US$6,070,000,
financed with a purchase money mortgage of US$3,000,000, and US$3,070,000 in cash.
On
April 2, 2019, the Company disposed of the real property located at 801 Andrews Avenue, Delray Beach for gross proceeds of $3,500,000.
Since
June 30, 2020, the Company has been actively involved in the operation of the treatment center operated by Evernia Health Center LLC
(“Evernia”) at 950 Evernia Street, West Palm Beach Florida. The Company is under contract to purchase a majority interest
in this company and has been financing the startup operations of this facility. This operation will be the Company’s only treatment
center operating and expects the purchase of the majority interest to close in the second quarter of 2021.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
2.
|
Summary of significant accounting
policies
|
Financial
Reporting
The
(a) unaudited condensed consolidated balance sheets as of March 31, 2021, which have been derived from the unaudited condensed consolidated
financial statements, and as of December 31, 2020, which have been derived from audited consolidated financial statements, and (b) the
unaudited condensed consolidated statements of operations and cash flows of the Company, have been
prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial
information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal
recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March
31, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. These unaudited condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company’s Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (“SEC”)
on April 15, 2021.
All
amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless
stated otherwise.
The
preparation of condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual
results could differ from those estimates.
|
|
b)
|
Principals of consolidation and
foreign currency translation
|
The
accompanying condensed consolidated financial statements include the accounts of the Company and all of its subsidiaries. All
intercompany transactions and balances have been eliminated on consolidation.
Certain
of the Company’s subsidiaries functional currency is the Canadian dollar, while the Company’s reporting currency is the U.S.
dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign Currency
Translation” as follows:
|
|
●
|
Monetary
assets and liabilities at the rate of exchange in effect at the balance sheet date.
|
|
|
●
|
Non-monetary,
non-current and equity at historical rates.
|
|
|
●
|
Revenue
and expense items and cash flows at the average rate of exchange prevailing during the period.
|
Adjustments
arising from such translations are deferred until realization and are included as a separate component of stockholders’ deficit
as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments are not included in determining
net income (loss) but reported as other comprehensive income (loss).
For
foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective
on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange
transaction gain or loss results which is included in determining net income for the period.
The
relevant translation rates are as follows: For the three months ended March 31, 2021, a closing rate of CDN$1.0000 equals US$0.7952 and
an average exchange rate of CDN$1.0000 equals US$0.7899. For the three months ended March 31, 2020, a closing rate of CAD$1.0000 equals
US$0.7049 and an average exchange rate of CAD$1.0000 equals US$0.7435.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
2.
|
Summary of significant accounting
policies (continued)
|
ASC
606 requires companies to exercise more judgment and recognize revenue using a five-step process.
The
Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate
line item on the consolidated statements of operations and comprehensive loss.
As
our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC
606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at
the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance
obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.
The
Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual
patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected
the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component.
The
Company derives a significant portion of its revenue from other payors that receive discounts from established billing rates. The various
managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may
include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost
settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable
regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that
could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations
occur frequently, necessitating regular review and assessment of the estimation process by management.
Settlements
with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future
periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final
settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the
Company’s financial condition or results of operations. The Company’s receivables were $3,113 and $3,075 for the three months
ended March 31, 2021 and for the year ended December 31, 2020, respectively. Management believes that these receivables are properly
stated and are not likely to be settled for a significantly different amount.
The
Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that
reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from
the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to
be recognized as it fulfills its obligations under each of its revenue transactions:
|
|
i.
|
identify the contract with a customer;
|
|
|
ii.
|
identify the performance obligations
in the contract;
|
|
|
iii.
|
determine the transaction price;
|
|
|
iv.
|
allocate the transaction price to
performance obligations in the contract; and
|
|
|
v.
|
recognize revenue as the performance
obligation is satisfied.
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
2.
|
Summary of significant accounting
policies (continued)
|
|
|
d)
|
Cash and cash equivalents
|
For
purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months
or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institutions
in the USA and Canada.
The
Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which
are insured by the Federal Deposit Insurance Corporation up to a limit of $250,000 per institution, in Canada which are insured by the
Canadian Deposit Insurance Corporation up to a limit of CDN$100,000 per institution.
Accounts
receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net
of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical
to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s consolidated financial
statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk
of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the
risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit
insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource
and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the
risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not
covered by insurance) and (vi) the risk of non-payment from uninsured patients.
|
|
f)
|
Allowance for Doubtful Accounts,
Contractual and Other Discounts
|
The
Company derives the majority of its revenues from commercial payors at out-of-network rates. Management estimates the allowance for contractual
and other discounts based on its historical collection experience. The services authorized and provided and related reimbursement are
often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s
allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts,
creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account is written
off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances
are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.
The
Company initially measures its financial assets and liabilities at fair value, except for certain non-arm’s length transactions.
The Company subsequently measures all its financial assets and financial liabilities at amortized cost.
Financial
assets measured at amortized cost include cash and accounts receivable.
Financial
liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, harmonized sales tax payable,
withholding taxes payable, convertible notes payable, loans payable and related party notes.
Financial
assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized
in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the
allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment
not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs
in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted
by the transaction costs that are directly attributable to their origination, issuance or assumption.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
2.
|
Summary of significant accounting
policies (continued)
|
|
|
g)
|
Financial instruments (continued)
|
FASB
ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles,
and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs
used in measuring fair value as follows:
|
|
●
|
Level
1. Observable inputs such as quoted prices in active markets;
|
|
|
●
|
Level
2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
|
|
|
●
|
Level
3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions.
|
The
Company measures its convertible debt and derivative liabilities associated therewith at fair value. These liabilities are revalued periodically
and the resultant gain or loss is realized through the Statement of Operations and Comprehensive Loss.
|
|
h)
|
Property and equipment
|
Property
and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset:
The
Company accounts for leases in terms of AC 842 whereby leases are classified as either capital or operating leases. Leases that transfer
substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as capital leases. At
the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition
and financing. Equipment recorded under capital leases is amortized on the same basis as described above. Operating leases are recognized
on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more than twelve
months. Payments under operating leases are expensed as incurred.
The
Company accounts for income taxes under the provisions of ASC Topic 740, “Income Taxes”. Under ASC Topic
740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated
financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes are provided
using the liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences
by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the
tax bases of existing assets and liabilities. The tax basis of an asset or liability is the amount attributed to that asset or liability
for tax purposes. The effect on deferred taxes of a change in tax rates is recognized in income in the period of change. A valuation
allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion of, or all
of, the deferred tax assets will not be realized.
ASC
Topic 740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax
return. The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax
position will be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to
measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company
recognizes interest and penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that
accrued interest and penalties
do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses
in the period that such determination is made.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
2.
|
Summary of significant accounting
policies (continued)
|
|
|
k)
|
Net income (loss) per Share
|
Basic
net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the period.
Diluted
net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding.
Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.
Dilution
is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and
warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained
thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted
method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of
the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable
to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion
will be assumed only if it reduces earnings per share (or increases loss per share).
|
|
l)
|
Stock based compensation
|
Stock
based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over
the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized
in the consolidated statements of operations is based on awards ultimately expected to vest and has been reduced for estimated forfeitures.
This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have minimal awards with performance
conditions and no awards dependent on market conditions.
The
Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine
whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value
with changes in fair value recorded in earnings. The Company uses a Black Scholes Option Pricing model to estimate the fair value of
convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives during
each reporting period are included in the statements of operations. Inputs into the Black Scholes Option Pricing model require estimates,
including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life of the financial
instruments being fair valued.
If
the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt
with Conversion and Other Options” for consideration of any beneficial conversion feature.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
2.
|
Summary of significant accounting
policies (continued)
|
|
|
n)
|
Recent accounting pronouncements
|
The
FASB issued several additional updates during the period, none of these standards are either applicable to the Company or require adoption
at a future date and none are expected to have a material impact on the consolidated financial statements upon adoption.
|
|
o)
|
Financial instruments Risks
|
The
Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s
risk exposure and concentrations at the balance sheet date, March 31, 2021 and December 31, 2020.
Credit
risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an
obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.
Credit
risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized
as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located
in the US.
In
the opinion of management, credit risk with respect to accounts receivable is assessed as low.
Liquidity
risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity
risk through its working capital deficiency of $12,672,306, which includes derivative liabilities of $4,379,372, and an accumulated deficit
of $44,858,784. The Company is dependent upon the raising of additional capital in order to implement its business plan. There is no
assurance that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material
adverse effect on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material
and remains unchanged from that of the prior year.
Market
risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices.
Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest
rate risk and currency risk.
Interest
rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market
interest rates. The Company is exposed to interest rate risk on its convertible debt, mortgage loans, short term loans, third party loans
and government assistance loans as of March 31, 2021. In the opinion of management, interest rate risk is assessed as moderate.
Currency
risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign
exchange rates. The Company is subject to currency risk as it has subsidiaries that operate in Canada and are subject to
fluctuations in the Canadian dollar. A substantial portion of the Company’s financial assets and liabilities are denominated
in Canadian dollars. Based on
the net exposures at March 31, 2021, a 5% depreciation or appreciation of the Canadian dollar against the U.S. dollar would result in
an approximate $4,526 increase or decrease in the Company’s after tax net income from operations. The Company has not entered into
any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged
from that of the prior year.
Other
price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market
prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the
individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion
of management, the Company is not exposed to this risk and remains unchanged from the prior year.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The
Company’s condensed consolidated financial statements have been prepared in accordance with US GAAP applicable to a going
concern, which assumes that the Company will be able to meet its obligations and continue its operations in the normal course of
business. As at March 31, 2021 the Company has a working capital deficiency of $12,672,306, including derivative liabilities of
$4,379,372 and accumulated deficit of $44,858,784. Management believes that current available resources will not be sufficient to
fund the Company’s planned expenditures over the next 12 months. Accordingly, the Company will be dependent upon the raising
of additional capital through placement of common shares, and/or debt financing in order to implement its business plan and
generating sufficient revenue in excess of costs. If the Company raises additional capital through the issuance of equity securities
or securities convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or
privileges senior to those of the holders of common stock or convertible senior notes. If the Company raises additional funds by
issuing debt, the Company may be subject to limitations on its operations, through debt covenants or other restrictions. If the
Company obtains additional funds through arrangements with collaborators or strategic partners, the Company may be required to
relinquish its rights to certain geographical areas, or techniques that it might otherwise seek to retain. There is no assurance
that the Company will be successful with future financing ventures, and the inability to secure such financing may have a material
adverse effect on the Company’s financial condition. These consolidated financial statements do not include any adjustments to
the amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue
operations.
The
ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock or
obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and
obtaining debt financing to fund its capital requirements and ongoing operations; however, there can be no assurance the Company will
be successful in these efforts.
These
factors create substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated
financial statements do not include any adjustments relating to the recoverability or classification of recorded assets and
liabilities or other adjustments that may be necessary should the Company not be able to continue as a going concern.
Other
current assets includes the following:
On
February 25, 2019, the Company entered into a Letter of Intent whereby it would purchase a 33.33% interest in Local Link Wellness, LLC
(“LLW”) for gross proceeds of $400,000. LLW proposes to provide a comprehensive addiction treatment program to large employee
groups. The company has advanced LLW a total of $120,000 at March 31, 2021. These funds were advanced as short-term promissory notes
that are immediately due and payable and are classified as other current assets on our consolidated balance sheet.
The
Company has no intention to close on the purchase of LLW and is currently negotiating with the vendors to provide advertising services
in lieu of the return of the $120,000 invested by the Company.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
On
June 30, 2020, the Company entered into an agreement whereby the Company will acquire 51% of American Treatment Holdings, Inc. (“ATHI”)
from The Q Global Trust (“Seller”) and Lawrence B Hawkins (“Hawkins”), which in turn owns 100% of Evernia Health
Services LLC. (“Evernia”), which operates drug rehabilitation facilities. The consideration for the acquisition is a loan
to be provided by the purchaser to Evernia in the amount of $500,000. As of March 31, 2021, the Company had advanced Evernia approximately
$1,026,669 including accrued interest thereon.
The
Company originally had a 180 day option, from the advancement of the first tranche to Evernia, to purchase an additional 9% of ETHI for
a purchase consideration of $50,000. The option has been extended and the Company had made a down payment of $10,000 towards exercising
this option.
On
June 30, 2020, the Company entered into an agreement whereby the Company will acquire 51% of Behavioral Health Holdings, Inc. (“BHHI”)
from The Q Global Trust (“Seller”) and Lawrence B Hawkins, which in turn owns 100% of Peace of Mind Counseling Services,
Inc. (“PMCS”), which operates drug rehabilitation facilities. The consideration for the acquisition is still to be determined. The
Company is currently considering its options to acquire a stake in BHHI and may renegotiate the deal terms.
On
July 12, 2020, the Company entered into a five year option agreement with Leonite Capital LLC (“Leonite”) and other investors
(collectively the “Transferees”), the Company agreed to sell to Leonite a portion of the total outstanding shares of ATHI
from the shares of ATHI held by the company. The Company provided Leonite an option to purchase a 33% of ATHI from the Company for a
purchase consideration of $0.0001 per share, based on the advances that Leonite made to the Company totaling $655,000. Leonite shall
share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Leonite to the Company, thereafter
the option will be reduced to 50% of the shares exercisable under the option.
On
September 14, 2020, the Company entered into a five year option agreement with Ed Blasiak (“Blasiak”) whereby the Company
agreed to sell to Blasiak a portion of the total outstanding shares of ATHI. The Company provided Blasiak an option to purchase 2.5%
of ATHI from the Company for a purchase consideration of $0.0001 per share, based on the advances that Blasiak made to the Company totaling
$50,000. Blasiak shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Blasiak
to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.
On
October 29, 2020, the Company entered into a five year option agreement with First Fire whereby the Company agreed to sell to First Fire
a portion of the total outstanding shares of ATHI. The Company provided First Fire an option to purchase 6.25% of ATHI from the Company
for a purchase consideration of $0.0001 per share, based on the advances that First Fire made to the Company totaling $125,000. First
Fire shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by First Fire to the
Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.
On
October 29, 2020, the Company entered into a five year option agreement entered into with Bauman, so that the Company agreed to sell
to Bauman a portion of the total outstanding shares of ATHI. The Company provided Bauman an option to purchase 6.25% of ATHI from the
Company for a purchase consideration of $0.0001 per share, based on the advances that Bauman made to the Company totaling $125,000. Bauman
shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Bauman to the Company,
thereafter the option will be reduced to 50% of the shares exercisable under the option.
|
6.
|
Due on sale of business
|
On
February 14, 2017, the Company sold its Canadian Rehab Clinic for gross proceeds of CDN$10,000,000, of which CDN$1,500,000 had been retained
in an escrow account for a period of up to two years in order to guarantee the warranties provided by the Company in terms of the APA.
As of March 31, 2021, CDN$1,055,042 of the escrow had been refunded to the Company and CDN$461,318 had been used to affect building improvements
to the premises owned by CCH, for a total reduction of CDN$1,516,360. The remaining escrow balance was CDN$6,485 (approximately US$ 5,157).
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
7.
|
Property and equipment
|
Property
and equipment consists of the following:
|
|
|
March
31,
2021
|
|
December
31, 2020
|
|
|
|
Cost
|
|
Accumulated
depreciation
|
|
Net
book value
|
|
Net
book value
|
|
Land
|
|
$
|
170,974
|
|
|
$
|
—
|
|
|
$
|
170,974
|
|
|
$
|
168,866
|
|
|
Property
|
|
|
3,234,310
|
|
|
|
(519,423
|
)
|
|
|
2,714,887
|
|
|
|
2,713,354
|
|
|
|
|
$
|
3,405,284
|
|
|
$
|
(519,423
|
)
|
|
$
|
2,885,861
|
|
|
$
|
2,882,220
|
|
Depreciation
expense for the three months ended March 31, 2021 and 2020 was $32,125 and $30,241, respectively.
The
taxes payable consist of:
|
|
●
|
A
payroll tax liability of $145,200 (CDN$182,589) in Greenstone Muskoka which has not been settled as yet.
|
|
|
●
|
A
GST/HST tax payable of $87,492 (CDN$110,022).
|
|
|
●
|
The Company has assets
and operates businesses in Canada and is required to disclose these operations to the US taxation authorities, the requisite disclosure
has not been made. Management has reserved the maximum penalty due to the IRS in terms of non-disclosure. This noncompliance with
US disclosure requirements is currently being addressed. An amount of $250,000 has been accrued for any potential exposure the Company
may have.
|
|
|
|
March 31,
2021
|
|
December 31,
2020
|
|
|
|
|
|
|
|
Payroll taxes
|
|
$
|
145,200
|
|
|
$
|
143,410
|
|
|
HST/GST payable
|
|
|
87,493
|
|
|
|
73,503
|
|
|
US penalties due
|
|
|
250,000
|
|
|
|
250,000
|
|
|
Income tax payable
|
|
|
388,150
|
|
|
|
383,364
|
|
|
|
|
$
|
870,843
|
|
|
$
|
850,277
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
|
The
short-term convertible notes consist of the following:
|
|
|
|
Interest rate
|
|
|
Maturity Date
|
|
|
Principal
|
|
|
|
Interest
|
|
|
|
Debt Discount
|
|
|
|
March
31,
2021
|
|
|
|
December 31,
2020
|
|
|
Leonite Capital, LLC
|
|
|
8.5
|
%
|
|
—
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
70,583
|
|
|
|
|
|
6.5
|
%
|
|
June 12, 2021
|
|
|
677,874
|
|
|
|
6,763
|
|
|
|
(340,016
|
)
|
|
|
344,621
|
|
|
|
147,058
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Fire Global Opportunities Fund
|
|
|
6.5
|
%
|
|
October 29,2021
|
|
|
138,889
|
|
|
|
3,821
|
|
|
|
(80,841
|
)
|
|
|
61,869
|
|
|
|
25,297
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Auctus Fund, LLC
|
|
|
10.0
|
%
|
|
May 7, 2020
|
|
|
115,000
|
|
|
|
—
|
|
|
|
—
|
|
|
|
115,000
|
|
|
|
150,000
|
|
|
|
|
|
10.0
|
%
|
|
August 13, 2021
|
|
|
95,000
|
|
|
|
6,139
|
|
|
|
(35,137
|
)
|
|
|
66,002
|
|
|
|
40,202
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Labrys Fund, LP
|
|
|
12.0
|
%
|
|
November 30, 2021
|
|
|
275,000
|
|
|
|
11,053
|
|
|
|
(183,836
|
)
|
|
|
102,217
|
|
|
|
26,159
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ed Blasiak
|
|
|
6.5
|
%
|
|
September 14, 2021
|
|
|
55,000
|
|
|
|
1,966
|
|
|
|
(25,164
|
)
|
|
|
31,802
|
|
|
|
17,347
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Joshua Bauman
|
|
|
6.5
|
%
|
|
September 14, 2021
|
|
|
138,889
|
|
|
|
4,819
|
|
|
|
(63,817
|
)
|
|
|
79,891
|
|
|
|
43,247
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Geneva Roth Remark Holdings, Inc.
|
|
|
9.0
|
%
|
|
August 29, 2021
|
|
|
88,000
|
|
|
|
2,431
|
|
|
|
(43,711
|
)
|
|
|
46,720
|
|
|
|
19,238
|
|
|
|
|
|
9.0
|
%
|
|
October 15, 2021
|
|
|
53,000
|
|
|
|
1,670
|
|
|
|
(31,033
|
)
|
|
|
23,637
|
|
|
|
6,753
|
|
|
|
|
|
9.0
|
%
|
|
January 3, 2022
|
|
|
53,500
|
|
|
|
374
|
|
|
|
(48,605
|
)
|
|
|
5,269
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series N convertible notes
|
|
|
6.0
|
%
|
|
On Demand
|
|
|
3,229,000
|
|
|
|
473,105
|
|
|
|
—
|
|
|
|
3,702,105
|
|
|
|
3,654,333
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
4,579,133
|
|
|
$
|
4,200,217
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
Leonite
Capital, LLC
On
December 1, 2017, the Company closed on a private offering to raise US $1,500,000 in capital. The Company issued one senior secured convertible
promissory note with a principal amount of $1,650,000 to Leonite Capital, LLC (“Leonite”). The note is convertible into shares
of common stock at a conversion price of $0.06 per share, subject to anti-dilution and price protection. The Note bears interest at the
rate of 8.5% per annum. The Note’s amended maturity date was December 1, 2018. During the term of the Note the Company and the
Subsidiaries was obligated to make monthly payment of accrued and unpaid interest. The Note contains Company and Subsidiary representations
and warranties, covenants, events of default, and registration rights. The Company paid a commitment fee of $132,000 settled through
the issue of 1,650,000 shares of common stock and paid $20,000 towards the lenders legal fees. In conjunction with this note, the Company
issued a five year warrant to purchase 27,500,000 shares of common stock at an exercise price or $0.10 per share, subject to anti-dilution
and price protection.
The
Note provided that the parties use reasonable best efforts to close on the remaining $1,200,000 of availability under the Note by January
1, 2018. As a condition to the closing of the Balance Tranche, the parties must finalize and enter into additional agreements related
to the Private Offering, including, but not limited to, (i) a Securities Purchase Agreement; (ii) a Warrant Agreement under which the
Investor will have the right to purchase up to 27,500,000 shares of the Company’ common stock for $0.10 per share, subject to adjustment,
for a period of five years; (iii) a Securities Pledge Agreement under which the Company and the Subsidiaries will grant the lender a
blanket lien on their assets, and the Company will pledge its equity ownership in the Subsidiaries. Upon the closing of the Balance Tranche
the maturity date of the Note was to become December 1, 2018.
On
December 29, 2017, effective as of December 1, 2017, the Company and the Subsidiaries entered into an Amended and Restated Senior Secured
Convertible Promissory Note, which note amended and restated the Note to (a) extend the maturity date to December 1, 2018; (b) remove
CCH, as an obligor; (c) increase the interest rate by 2.00% per annum, to 8.5% per annum; and (d) issue an additional 250,000 shares
of the Company’s common stock to the Investor. In connection with the execution of the amendment, the parties entered into (i)
a Securities Purchase Agreement; (ii) a Warrant Agreement under which the Investor will have the right to purchase up to 27,500,000 shares
of the Company’ common stock for $0.10 per share, subject to adjustment, for a period of five years; (iii) a Security and Pledge
Agreement and a General Security Agreement under which the Company and the Subsidiaries will grant the Investor a blanket lien on their
assets, and the Company will pledge its equity ownership in the Subsidiaries; effective January 2, 2018.
At
the execution of the Note, the Investor funded an initial tranche of $300,000. Thereafter the Investor funded a second tranche of $156,136.
Upon the execution of the A&R Note the Investor funded a third tranche of $100,000. Upon the execution of the First Amendment the
Investor funded a final tranche of $850,000, with the remaining $93,764 of availability under the A&R Note, as amended, serving as
a holdback pursuant to the terms of the First Amendment.
On
March 29, 2018, the Company, entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $165,000, including an Original Issue Discount of $15,000, for net proceeds of $150,000. The
note had a maturity date of December 1, 2018 and bears interest at a rate of 8.5% per annum. The outstanding principal amount of the
note is convertible at any time and from time to time at the election of the purchaser following the issue date into shares of the Company’s
common stock at a conversion price equal to $0.06 per share subject to anti-dilution and price protection. The Company paid a commitment
fee of $11,550 settled through the issue of 165,000 shares of common stock. In conjunction with this note the Company issued a five year
warrant to purchase 5,500,000 shares of common stock at an exercise price of $0.10 per share, subject to anti-dilution and price protection.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
Leonite
Capital, LLC (continued)
On
April 17, 2018, the Company, entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $605,000, including an Original Issue Discount of $55,000, for net proceeds of $550,000. The
note had a maturity date of December 1, 2018 and bears interest at 8.5% per annum. The outstanding principal amount of the note is convertible
at any time and from time to time at the election of the purchaser following the issue date into shares of the Company’s common
stock at a conversion price equal to $0.06 per share subject to price protection and anti-dilution protection. The Company paid a commitment
fee of $42,350 settled through the issue of 10,083,333 shares of common stock. In conjunction with this note the Company issued a five
year warrant to purchase 10,083,333 shares of common stock at an exercise price of $0.10 per share, subject to anti-dilution and price
protection.
On
January 17, 2019, the Company, entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $71,111, including an Original Issue Discount of $7,111, for net proceeds of $64,000. The note
had a maturity date of July 25, 2019 and bears interest at 11.0% per annum. The outstanding principal amount of the note was convertible
at any time and from time to time at the election of the purchaser following the issue date into shares of the Company’s common
stock at a conversion price equal to $0.06 per share subject to price protection and anti-dilution protection. The Company paid a commitment
fee of $4,978 settled through the issue of 71,111 shares of common stock. In conjunction with this note the Company issued a five year
warrant to purchase 1,185,183 shares of common stock at an exercise price of $0.10 per share, subject to anti-dilution and price protection.
Effective
March 19, 2019, the Company entered into a note extension agreement with Leonite, whereby the convertible notes outstanding to Leonite,
amounting to $2,420,000, for consideration of $75,000 added to the principal outstanding on the note on January 1, 2019, a further $75,000
added to the principal outstanding on the note on February 1, 2019 and a further $100,000 added to the principal of the note on March
15, 2019, the maturity date of all of the convertible notes above were extended to December 31, 2019 and has subsequently been partially
settled by the transfer of the property located at 810 Andrews Avenue, Delray Beach, Florida, valued at $1,500,000.
On
August 26, 2019, the Company, entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $60,000, including an Original Issue Discount of $10,000, for net proceeds of $47,000. The
note had a maturity date of September 10, 2019 and bears interest at 1.0% per annum. The outstanding principal amount of the note is
convertible at any time and from time to time at the election of the purchaser following the issue date into shares of the Company’s
common stock at a conversion price equal to $0.06 per share subject to price protection and anti-dilution protection. In conjunction
with this note the Company issued a five year warrant to purchase 1,000,000 shares of common stock at an exercise price of $0.10 per
share, subject to anti-dilution and price protection.
On
October 10, 2019, the Company transferred a warranty deed to the real property located at 810 Andrews Avenue, Delray Beach, Florida to
Leonite Capital LLC, in settlement of indebtedness of $1,398,514 and additional expenses related to the disposal of the property of $36,470.
These expenses of $36,470 were provided for resulting in net proceeds recognized on the transfer of the property of $1,362,044.
On
July 12, 2020, the company entered into a debt extinguishment agreement with Leonite whereby the following occurred:
|
|
1.
|
The total amount outstanding under the note, including principal and interest was reduced to $150,000
|
|
|
2.
|
$700,000 of the note was converted into Series A Redeemable Preferred shares in the Company’s subsidiary, Cranberry Cove Holdings, accruing dividends at 10% per annum.
|
|
|
3.
|
$400,000 of the note was converted into series B Preferred stock in the Company for a 12 month period, mandatorily redeemable by the Company accruing dividends at 6% per annum payable in cash or stock, subject to certain conditions.
|
|
|
4.
|
The remaining balance of $150,000 will accrue interest at 8.5% per annum and is convertible into common stock and repayable in 6 monthly installments of $25,000 commencing after December 12, 2020.
|
|
|
5.
|
The existing warrants were cancelled and a new five year warrant, with a cashless exercise options, exercisable for a minimum of 326,286,847 shares of common stock and a maximum of 20% of the outstanding equity of the Company at an initial exercise price of $0.10 per share subject to adjustment based on new stock issuances or the lowest volume weighted exercise price of the stock for 30 days immediately preceding the exercise was issued to Leonite.
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
Leonite
Capital, LLC (continued)
On
December 28, 2020, Leonite converted $80,000 plus accrued interest of $5,949 of the Leonite loan amended on July 12, 2020, into 96,331,811
shares of common stock at a conversion price of $0.0009, thereby realizing a loss on conversion of $240,616. On January 8, 2021, Leonite
converted the remaining principal amount of $70,000, plus accrued interest thereon of $137, into 78,763,466 shares of common stock at
a conversion price of $0.0009 per share.
On
July 12, 2020, the Company entered into a Senior Secured Convertible Note agreement with Leonite for $440,000 with an original issue
discount of $40,000 for gross proceeds of $400,000, the initial tranche advanced will be for cash of $200,000 plus the OID of $20,000,
the remaining advances will be at the discretion of the Leonite. The loan bears interest at 6.5% per annum and matures on June 12, 2021.
The Company is required to make monthly payments of the accrued interest on the advances made. The note is convertible into common shares
at the option of the holder at $0.10 per share, or 80% multiplied by the price per share paid in subsequent financings or after a six
month period from the effective date at 60% of the lowest trading price during the preceding 21 consecutive trading days. The note has
both conversion price protection and anti-dilution protection provisions.
On
July 12, 2020, the Company entered into a five year option agreement with Leonite Capital LLC (“Leonite”) and other investors
(collectively the “Transferees”), the Company agreed to sell to Leonite a portion of the total outstanding shares of ATHI
from the shares of ATHI held by the company. The Company has provided Leonite an option to purchase 33% of ATHI from the Company for
a purchase consideration of $0.0001 per share, based on the advances that Leonite made to the Company totaling $655,000. Leonite shall
share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Leonite to the Company, thereafter
the option will be reduced to 50% of the shares exercisable under the option.
On
January 8, 2021, in terms of a conversion notice, Leonite converted the principal sum of $70,000 and interest thereon of $137 of the
Leonite loan into 78,763,466 shares of common stock at a conversion price of $0.009 per share.
In
terms of clause 3.12 of the Senior secured convertible Promissory Note Agreement (“Leonite Note”) entered into with Leonite
and the amendments thereto, the terms of the convertible promissory note issued to Labrys Fund LP on November 30, 2020, as described
below, contained terms more favorable than those contained in the Leonite Note, resulting in an adjustment made to the Original issue
discount of $4,000 and the issuance of five year warrants exercisable for 145,454,547 shares of common at an exercise price of $0.00205
per share, for all advances made to the Company by Leonite in terms of the Leonite Note, up to and including December 31, 2020.
On
January 8, January 22, February 4, and February 19, 2021, Leonite advanced the company an aggregate cash amount of $290,000, including
a revised original issue discount of $74,556 for an aggregate principal sum added to the Leonite Note of $364,556.
On
March 3, 2021, in terms of a conversion notice, Leonite converted the principal sum of $82,681 and interest thereon of $12,319 of the
Leonite Note into 97,000,000 shares of common stock at a conversion price of $0.009 per share.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
Power
Up Lending Group LTD
On
July 8, 2019, the Company entered into a Securities Purchase Agreement with Power Up, pursuant to which the Company issued a Convertible
Promissory Note in the aggregate principal amount of $53,000. The Note had a maturity date of April 30, 2020 and bore interest at the
rate of nine percent per annum from the date on which the Note was issued until the same becomes due and payable, whether at maturity
or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding
principal amount of the Note is convertible at any time and from time to time at the election of Power Up during the period beginning
on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to
61% of the lowest closing bid price of the Company’s common stock for the ten trading days prior to conversion.
Between
January 10, 2020 and January 24, 2020, in terms of conversion notices received, Power Up converted the aggregate principal amount of
$53,000 and interest thereon of $1,085 into 75,618,509 shares of common stock at an average conversion price of $0.000715 per share.
On
July 15 2019, the Company, entered into a Securities Purchase Agreement with Power Up, pursuant to which the Company issued a Convertible
Promissory Note in the aggregate principal amount of $83,000. The Note has a maturity date of April 30, 2020 and bears interest at the
rate of nine percent per annum from the date on which the Note was issued until the same becomes due and payable, whether at maturity
or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding
principal amount of the Note is convertible at any time and from time to time at the election of Power Up during the period beginning
on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to
61% of the lowest closing bid price of the Company’s common stock for the ten trading days prior to conversion.
Between
January 24, 2020 and February 27, 2020, in terms of conversion notices received, Power Up converted the aggregate principal amount of
$41,400 into 453,800,493 shares of common stock at an average conversion price of 0.0000912 per share.
On
June 1, 2020, The Company repaid the Power Up Lending Group $41,600 in full settlement of the convertible note entered into on July 15,
2019.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
First
Fire Global Opportunities Fund
On
March 5, 2019, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $200,000, for net proceeds of $192,000 after the payment of legal fees and origination fees
amounting to $8,000. The note has a maturity date of December 9, 2019. The outstanding principal amount of the note is convertible at
any time and from time to time at the election of the purchaser. 180 days after the issued date into shares of the Company’s common
stock at the lower of $0.08 per share or 65% of the lowest trade price during the ten consecutive trading days immediately prior to conversion.
The note has certain buyback terms if the Company consummates a registered or unregistered primary offering of securities for capital
raising purposes, or an option to convert at a 20% discount to the offering price to investors.
Between
September 11, 2019 and December 30, 2019, in terms of a conversion notices received, the Company issued 11,887,445 shares of Common stock
in settlement of $36,592 of principal outstanding.
Between
January 6, 2020 and February 26, 2020, in terms of conversion notices received, First Fire converted an aggregate principal amount of
$83,902 into 308,100,000 shares of common stock at an average conversion price of $0.000272 per share.
On
June 3, 2020, the Company entered into an agreement with First Fire whereby the remaining balance of the convertible note of $73,006
would be settled by two payments of $25,000 each.
Between
July 2, 2020 and August 17, 2020, the Company repaid the remaining principal outstanding of $50,000 plus additional interest charges
of $1,500.
On
October 29, 2020, the Company entered into a Securities Purchase Agreement, pursuant to which the Company issued a senior secured convertible
promissory note in the aggregate principal amount of $137,500, including an OID of $12,500. The note bears interest at 6.5% per annum
and matures on October 29, 2021. The note is senior to any future borrowings and commencing on November 29, 2020 the Company will make
monthly payments of the accrued interest under the note. The note may be prepaid at certain prepayment penalties and is convertible into
shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions;
or 80% of the price per share of subsequent equity financings or; after six months 60% of the lowest trading price during the preceding
six month period.
On
October 29, 2020, the Company entered into a five year option agreement with First Fire whereby the Company agreed to sell to First Fire
a portion of the total outstanding shares of ATHI. The Company provided First Fire an option to purchase 6.25% of ATHI from the Company
for a purchase consideration of $0.0001 per share, based on the advances that First Fire made to the Company totaling $125,000. First
Fire shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by First Fire to the
Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.
In
terms of clause 3.12 of the Senior secured convertible Promissory Note Agreement (“First Fire Note”) entered into with First
Fire, the terms of the convertible promissory note issued to Labrys Fund LP on November 30, 2020, as described below, contained terms
more favorable than those contained in the First Fire Note, resulting in an adjustment made to the Original issue discount of $1,389
and the issuance of five year warrants exercisable for 50,505,051shares of common at an exercise price of $0.00205 per share, for the
advance made to the Company by First Fire in terms of the First Fire Note.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
Auctus
Fund, LLC
On
August 7 2019, the Company, entered into a Securities Purchase Agreement with Auctus Fund, LLC, pursuant to which the Company issued
a Convertible Promissory Note in the aggregate principal amount of $225,000. The Note had a maturity date of May 7, 2020 and bore interest
at the rate of ten percent per annum from the date on which the Note was issued until the same became due and payable, whether at maturity
or upon acceleration or by prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement. The outstanding
principal amount of the Note is convertible at any time and from time to time at the election of Auctus Fund, LLC during the period beginning
on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion price equal to
60% of the lowest closing bid price of the Company’s common stock for the thirty trading days prior to conversion.
On
June 15, 2020, The Company entered into an amended agreement with Auctus whereby Auctus agreed to discharge the principal amount of the
note by nine equal monthly installments of $25,000 commencing in October 2020. During the three months ended March 31, 2021, the Company
repaid Auctus the principal sum of $35,000.
On
August 13, 2020, the Company entered into a Securities Purchase Agreement with Auctus Fund LLC, pursuant to which the Company issued
a convertible promissory note in the aggregate principal amount of $100,000 for net proceeds of $85,000 after certain fees and expenses
of $15,000. The note has a maturity date of August 13, 2021 and bears interest at 10% per annum. The interest due on the note for the
full twelve month period is due immediately upon issuance of the note, regardless of acceleration or prepayment. The principal amount
of the note is payable in six monthly instalments of $16,666.66 commencing 180 days after the issuance date, the balance outstanding
under the note due at maturity date. In the event a default occurs under the Note, the Note is convertible into shares of common stock
at a conversion price equal to the lowest trading price over the prior 5 days prior to the date of the note or the five day volume weighted
market price prior to the date of conversion. The Company is required to adhere to certain covenants including covenants concerning distributions
of capital stock; restrictions on stock repurchases, additional borrowings sales of assets and loans and advances made by the Company.
In conjunction with the issuance of the promissory note, the Company issued a five year warrant exercisable for 66,666,666 shares of
common stock at an exercisable price of $0.0015 per share subject to anti-dilution and price protection adjustments. The Company also
issued a second five year warrant exercisable for 66,666,666 shares of common stock at an exercisable price of $0.0015 per share subject
to anti-dilution and price protection adjustments, which warrants will only be exercisable upon an event of default on the convertible
note.
On
March 9, 2021, Auctus exercised its warrant for 66,666,666 shares of common stock on a cashless exercise basis, resulting in the issue
of 59,999,999 shares of common stock.
Labrys
Fund, LP
On
July 8, 2019, the Company, entered into a Securities Purchase Agreement with Labrys Fund, LP (“Labrys”), pursuant to which
the Company issued a Convertible Promissory Note in the aggregate principal amount of $282,000 for net proceeds of $253,800 after an
original issue discount of $28,200. The Note had a maturity date of January 8, 2020 and bore interest at the rate of twelve percent per
annum from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by
prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement. The outstanding principal amount of the
Note was convertible at any time and from time to time at the election of Labrys during the period beginning on the date that is 180
days following the issue date into shares of the Company's common stock at a conversion price equal to 60% of the lowest closing bid
price of the Company's common stock for the thirty trading days prior to conversion.
In
connection with the issuance of the convertible promissory note to Labrys, the Company issued 2,700,000 returnable shares. These shares
were returnable if the note was paid prior to maturity date on January 8, 2020. The company had not repaid the note on the maturity date,
January 8, 2020, therefore the 2,700,000 shares were expensed as an additional fee amounting to $165,780, the value of the shares on
the date of grant.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
Labrys
Fund, LP (continued)
Between
January 15, 2020 and February 25, 2020, in terms of conversion notices received, Labrys converted the aggregate principal sum of $8,936
and interest of $19,867 into 479,160,076 shares of common stock at an average conversion price of 0.00006 per share.
On
May 15, 2020 the Company entered into an amended agreement with Labrys Fund LP whereby default interest and penalties were waived, no
further conversions will be effectuated and the Company committed to make eight equal payments of $25,000 commencing on October 15, 2020,
in full settlement of the balance outstanding. No event of default will occur as long as the Company makes all scheduled payments.
Between
October 21, 2020 and November 30, 2020, the Company repaid principal of $37,500. The Company was unable to adhere to the amended repayment
schedule and default penalty and penalty interest was reinstated.
On
November 30, 2020, Labrys converted principal of $235,564 and interest thereon of $20,416 into 91,421,457 shares of common stock, realizing
a gain on conversion of $4,571, thereby extinguishing the note.
On
November 30, 2020, the Company, entered into a Securities Purchase Agreement with Labrys, pursuant to which the Company issued a Convertible
Promissory Note in the aggregate principal amount of $275,000 for net proceeds of $239,050 after an original issue discount of $27,500
and certain legal expenses. The Note has a maturity date of November 30, 2021 and bears interest at the rate of twelve percent per annum
from the date on which the Note was issued until the same became due and payable, whether at maturity or upon acceleration or by prepayment
or otherwise. The Company has the right to prepay the Note in terms of agreement. The outstanding principal amount of the Note was convertible
at any time and from time to time at the election of Labrys during the period beginning on the date that is 180 days following the issue
date into shares of the Company's common stock at a conversion price equal to 60% of the lowest closing bid price of the Company's common
stock for the thirty trading days prior to conversion.
In
connection with the issuance of the convertible promissory note to Labrys, the Company granted Labrys a five-year warrant to purchase
100,000,000 shares of common stock at an exercise price of $0.00205 per share. The value of the warrant was accounted for as a debt discount.
Ed
Blasiak
On
September 14, 2020, the Company entered into a Securities Purchase Agreement with Ed Blasiak (“Blasiak”), pursuant to which
the Company issued a senior secured convertible promissory note in the aggregate principal amount of $55,000, including an original issue
discount of $5,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future borrowings
and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note may be prepaid
at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of the holder at $0.001
per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings or; after six months
60% of the lowest trading price during the preceding six month period.
On
September 14, 2020, the Company entered into a five year option agreement with Ed Blasiak (“Blasiak”) whereby the Company
agreed to sell to Blasiak a portion of the total outstanding shares of ATHI. The Company provided Blasiak an option to purchase 2.5%
of ATHI from the Company for a purchase consideration of $0.0001 per share, based on the advances that Blasiak made to the Company totaling
$50,000. Blasiak shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Blasiak
to the Company, thereafter the option will be reduced to 50% of the shares exercisable under the option.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
Joshua
Bauman
On
September 14, 2020, the Company entered into a Securities Purchase Agreement with Joshua Bauman (“Bauman”), pursuant to which
the Company issued a senior secured convertible promissory note in the aggregate principal amount of $110,000, including an original
issue discount of $10,000. The note bears interest at 6.5% per annum and matures on September 14, 2021. The note is senior to any future
borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The note
may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option of
the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings
or; after six months 60% of the lowest trading price during the preceding six month period.
On
October 29, 2020, the Company entered into a five year option agreement entered into with Bauman, so that the Company agreed to sell
to Bauman a portion of the total outstanding shares of ATHI. The Company provided Bauman an option to purchase 6.25% of ATHI from the
Company for a purchase consideration of $0.0001 per share, based on the advances that Bauman made to the Company totaling $125,000. Bauman
shall share in all distributions by ATHI to the Company, on an as exercised basis, equal to the advances made by Bauman to the Company,
thereafter the option will be reduced to 50% of the shares exercisable under the option.
In
terms of clause 3.12 of the Senior secured convertible Promissory Note Agreement (“Bauman Note”) entered into with Joshua
Bauman, the terms of the convertible promissory note issued to Labrys Fund LP on November 30, 2020, as described above, contained terms
more favorable than those contained in the Bauman Note, resulting in an adjustment made to the Original issue discount of $1,389 and
the issuance of five year warrants exercisable for 50,505,051 shares of common at an exercise price of $0.00205 per share, for the advance
made to the Company by Bauman in terms of the Bauman Note.
Geneva
Roth Remark Holdings, Inc
On
October 29, 2020, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $88,000, for net proceeds of $85,000 after the payment of legal fees and origination fees amounting
to $3,000. The note has a maturity date of August 29, 2021 and bears interest at the rate of 9.0% per annum. The outstanding principal
amount of the note is convertible at any time and from time to time at the election of the purchaser. 180 days after the issued date
into shares of the Company’s common stock at 61% of the lowest trade price during the ten consecutive trading days immediately
prior to conversion. The principal plus the accrued interest of the Note may be prepaid by the Company prior to the expiry of 180 days
from issuance date at a prepayment penalty ranging from 112% to 130%.
On
November 24, 2020, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $53,000, for net proceeds of $50,000 after the payment of legal fees and origination fees amounting
to $3,000. The note has a maturity date of October 15, 2021 and bears interest at the rate of 9.0% per annum. The outstanding principal
amount of the note is convertible at any time and from time to time at the election of the purchaser. 180 days after the issued date
into shares of the Company’s common stock at 61% of the lowest trade price during the ten consecutive trading days immediately
prior to conversion. The principal plus the accrued interest of the Note may be prepaid by the Company prior to the expiry of 180 days
from issuance date at a prepayment penalty ranging from 112% to 130%.
On
March 3, 2021, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued a Convertible Promissory
Note in the aggregate principal amount of $53,500, for net proceeds of $50,000 after the payment of legal fees and origination fees amounting
to $3,500. The note has a maturity date of January 3, 2022 and bears interest at the rate of 9.0% per annum. The outstanding principal
amount of the note is convertible at any time and from time to time at the election of the purchaser. 180 days after the issued date
into shares of the Company’s common stock at 61% of the lowest trade price during the ten consecutive trading days immediately
prior to conversion. The principal plus the accrued interest of the Note may be prepaid by the Company prior to the expiry of 180 days
from issuance date at a prepayment penalty ranging from 112% to 130%.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
9.
|
Short-term Convertible Notes
(continued)
|
Series
N convertible notes
Between
January 28, 2019 and June 11, 2020, the Company closed several tranches of Series N Convertible notes in which it raised $3,229,000
in principal from accredited investors through the issuance to the investors of the Company’s Series N convertible notes, in
the total original principal amount of $3,229,000, which Notes are convertible into the Company’s common stock at a conversion
price of $0.08 per share together with three year warrants to purchase up to a total of 52,237,500 shares of the Company’s
common stock at an exercise price of $0.12 per share. Both the conversion price under the Notes and the exercise price under the
warrants are subject to standard adjustment mechanisms. The notes mature one year from the date of issuance.
Mortgage
loans is disclosed as follows:
|
|
|
Interest
rate
|
|
|
Maturity
date
|
|
Principal
Outstanding
|
|
|
Accrued
interest
|
|
|
March
31,
2021
|
|
|
December
31,
2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cranberry Cove Holdings, Ltd.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pace Mortgage
|
|
|
4.2
|
%
|
|
July 19, 2022
|
|
$
|
3,978,909
|
|
|
$
|
5,495
|
|
|
$
|
3,984,404
|
|
|
$
|
3,963,781
|
|
|
Disclosed as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term portion
|
|
|
|
|
|
|
|
|
|
|
$
|
118,538
|
|
|
$
|
115,704
|
|
|
Long-term portion
|
|
|
|
|
|
|
|
|
|
|
|
3,865,866
|
|
|
|
3,848,077
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,984,404
|
|
|
$
|
3,963,781
|
|
The
aggregate amount outstanding is payable as follows:
|
|
|
Amount
|
|
Within the next twelve months
|
|
|
118,538
|
|
|
Thereafter
|
|
|
3,865,866
|
|
|
Total
|
|
$
|
3,984,404
|
|
Cranberry
Cove Holdings, Ltd.
On
July 19, 2017, CCH, a wholly owned subsidiary, closed on a loan agreement in the principal amount of CDN$5,500,000. The loan is secured
by a first mortgage on the premises owned by CCH located at 3571 Muskoka Road 169, Bala, Ontario. The loan bears interest at the fixed
rate of 4.2% with a 5-year primary term and a 25-year amortization. The Company has guaranteed the loan and the Company’s chief
executive officer and controlling shareholder also has personally guaranteed the Loan. CCH and the Company have granted the Lender a
general security interest in its assets to secure repayment of the Loan. The loan is amortized with monthly installments of CDN $29,531.
On
April 12, 2019, Eileen Greene, a related party assigned CDN1,000,000 of the amount owed by the Company to her, to a third party. The
loan bears interest at 12% per annum which the Company agreed to pay.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
12.
|
Government assistance loans
|
On
May 10, 2020, the Company was granted a government assistance loan in the aggregate principal amount of $156,782. The loan is forgivable
if the Company demonstrates that the proceeds were used for expenses such as employee costs during the pandemic. Should the loan not
be forgiven, interest is payable on the loan at the rate of 1% per annum and the principal is repayable and interest is payable over
an 18 month period. No payments have been made to date and the Company expects the loan to be forgiven, therefore no interest has been
accrued.
On
December 1, 2020, CCH was granted a Covid-19 related government assistance loan in the aggregate principal amount of CDN$ 40,000 (Approximately
$31,000). the grant is interest free and CDN$ 10,000 is forgivable if the loan is repaid in full by December 31, 2022.
On
January 12, 2021, CCH received a further CDN$ 20,000 Covid-19 related government assistance loan. The loan is interest free and if repaid
by December 31, 2022, CDN$ 10,000 is forgivable.
The
short-term convertible notes issued to convertible note holders disclosed in note 9 above, have variable priced conversion rights with
no fixed floor price and will reprice dependent on the share price performance over varying periods of time. This gives rise to a derivative
financial liability, which was initially valued at inception of the convertible notes at $109,574 using a Black-Scholes valuation model,
after taking into account the value of warrants issued to the convertible note holders.
The
derivative liability is marked-to-market on a quarterly basis. As of March 31, 2021, the derivative liability was valued at $4,379,372.
The
following assumptions were used in the Black-Scholes valuation model:
|
|
|
Three
months ended
March 31,
2021
|
|
|
|
|
|
Calculated stock price
|
|
|
$0.001 to $0.0055
|
|
|
Risk free interest rate
|
|
|
0.03% to 0.64
|
%
|
|
Expected life of convertible notes and warrants
|
|
|
3 to 60 months
|
|
|
expected volatility of underlying stock
|
|
|
157.4% to 299.1
|
%
|
|
Expected dividend rate
|
|
|
0
|
%
|
The
movement in derivative liability is as follows:
|
|
|
March 31,
2021
|
|
December 31,
2020
|
|
|
|
|
|
|
|
Opening balance
|
|
$
|
4,765,387
|
|
|
$
|
8,694,272
|
|
|
Derivative liability mark-to-market on convertible debt extinguishment
|
|
|
—
|
|
|
|
126,444,276
|
|
|
Derivative liability on revised convertible notes and warrants arising from convertible debt extinguishment
|
|
|
—
|
|
|
|
6,349,265
|
|
|
Derivative liability cancelled on debt extinguishment
|
|
|
—
|
|
|
|
(144,893,444
|
|
|
Derivative liability on issued convertible notes
|
|
|
109,574
|
|
|
|
1,129,050
|
|
|
Fair value adjustments to derivative liability
|
|
|
(495,589
|
)
|
|
|
7,041,968
|
|
|
|
|
|
|
|
|
|
|
|
|
Closing balance
|
|
$
|
4,379,372
|
|
|
$
|
4,765,387
|
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
14.
|
Related party transactions
|
Shawn
E. Leon
As
of March 31, 2021 and December 31, 2020 the Company had a payable to Shawn Leon of $322,744. Mr. Leon is a director and CEO of the Company.
The balances payable are non-interest bearing and has no fixed repayment terms.
Due
to the current financial position of the Group, Mr. Leon forfeited the management fees due to him for the three months ended March 31,
2021 and for the year ended December 31, 2020.
Leon
Developments, Ltd.
As
of March 31, 2021 and December 31, 2020, the Company owed Leon Developments, Ltd. $946,894 and $930,307, respectively, for funds advanced
to the Company.
Eileen
Greene
As
of March 31, 2021 and December 31, 2020, the Company owed Eileen Greene, the spouse of our CEO, Shawn Leon, $1,545,812 and $1,558,798,
respectively. The amount owing to Ms. Greene is non-interest bearing and has no fixed repayment terms.
All
related party transactions occur in the normal course of operations and in terms of agreements entered into between the parties.
|
15.
|
Stockholder’s deficit
|
Authorized
and outstanding
The
Company has authorized 10,000,000,000 shares with a par value of $0.01 per share. The company
has issued and outstanding 2,262,849,130 and 2,027,085,665 shares of common stock at March 31, 2021 and December 31, 2020, respectively.
On
January 8, 2021, the Company issued 78,763,466 shares of common stock to Leonite in connection with a conversion notice received, converting
principal and interest of $70,137.
On
March 3, 2021, the Company issued 97,000,000 shares of common stock to Leonite in connection with a conversion notice received, converting
principal and interest of $95,000.
On
March 9, 2021, the Company received notification of exercise of warrants for 66,666,666 shares on a cashless basis, resulting in the
issuance of 59,999,999 shares of common stock valued on the date of issuance at $90,000.
|
|
b)
|
Series A Preferred shares
|
Authorized,
issued and outstanding
The
Company has authorized 10,000,000 Series A preferred shares with a par value of $0.01 per share. The
company has issued and outstanding 4,000,000 Series A Preferred shares at March 31, 2021 and December 31, 2020, respectively.
|
|
c)
|
Series B Preferred shares
|
Authorized
and outstanding
The
Company has authorized 400,000 Series B preferred shares with a par value of $1.00 per share. The
company has issued and outstanding 400,000 Series B Preferred shares at March 31, 2021 and December 31, 2020, respectively.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
15.
|
Stockholder’s deficit (continued)
|
The Secured Promissory
Note Agreements entered into with Leonite, First Fire and Bauman contain certain conversion price protection and anti-dilution protection
provisions, which were triggered as a result of the terms contained in the promissory note issued to Labrys Fund LP on November 30, 2020.
As a result, the Company issued five year warrants exercisable for 246,464,649 shares of common at an exercise price of $0.00205 per
share, for all advances made to the Company by the lenders in terms of the secured Promissory Note Agreements.
Between
January 8, 2021 and February 19, 2021, Leonite advanced the Company an additional $290,000 and in terms of clause 3.12 of the Secured
Promissory Note Agreement entered into with Leonite, the Company granted Leonite five year warrants exercisable for 131,111,112 shares
of common stock at an exercise price of $0.00205 per share.
On
March 9, 2021, the Company received a cashless warrant exercise, exercising warrants for 66,666,666 shares for net shares of 59,999,999
shares of common stock.
A
summary of all of the Company’s warrant activity during the period January 1, 2020 to March 31, 2021 is as follows:
|
|
|
No.
of shares
|
|
Exercise
price per
share
|
|
Weighted
average exercise price
|
|
|
|
|
|
|
|
|
|
Outstanding as of January 1,
2020
|
|
|
2,566,101,248
|
|
|
|
$0.00204 to $0.12
|
|
|
$
|
0.0044700
|
|
|
Granted
|
|
|
233,333,332
|
|
|
|
0.0017357
|
|
|
|
0.0017357
|
|
|
Adjustment due to price protection
|
|
|
152,017,272,726
|
|
|
|
0.0000324
|
|
|
|
0.0000324
|
|
|
Forfeited/cancelled
|
|
|
(2,366,666
|
)
|
|
|
0.0300000
|
|
|
|
0.0300000
|
|
|
Granted in terms of debt
extinguishment
|
|
|
326,286,847
|
|
|
|
0.000675
|
|
|
|
0.0006750
|
|
|
Cancelled as part of debt
extinguishment
|
|
|
(154,300,675,861
|
)
|
|
|
0.0000324
|
|
|
|
0.0000324
|
|
|
Exercised
|
|
|
(224,390,247
|
)
|
|
|
0.0004
|
|
|
|
0.0004000
|
|
|
Outstanding as of December
31, 2020
|
|
|
615,561,379
|
|
|
|
$0.000675 to $0.12
|
|
|
|
0.0113796
|
|
|
Granted
|
|
|
377,575,761
|
|
|
|
$0.0020500
|
|
|
|
0.0020500
|
|
|
Forfeited/cancelled
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Exercised
|
|
|
(66,666,666
|
)
|
|
|
$0.0015000
|
|
|
|
$0.001500
|
|
|
Outstanding as of March
31, 2021
|
|
|
926,470,474
|
|
|
|
$0.000675
to $0.12
|
|
|
$
|
$0.0082883
|
|
The
warrants were valued using a Black Scholes pricing model on the date of grant at $1,565,487 using the following weighted average assumptions:
|
|
|
Three
months ended
March 31,
2021
|
|
Calculated stock price
|
|
|
$0.00205
|
|
|
Risk free interest rate
|
|
|
0.36 to 0.59
|
%
|
|
Expected life of warrants
|
|
|
60 months
|
|
|
expected volatility of underlying stock
|
|
|
226.2 to 231.3
|
%
|
|
Expected dividend rate
|
|
|
0
|
%
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
15.
|
Stockholder’s deficit (continued)
|
The
volatility of the common stock is estimated using historical data of the Company’s common stock. The risk-free interest rate used
in the Black Scholes pricing model is determined by reference to historical U.S. Treasury constant maturity rates with maturities approximate
to the life of the warrants granted. An expected dividend yield of zero is used in the valuation model, because the Company does not
expect to pay any cash dividends in the foreseeable future.
The
following table summarizes information about warrants outstanding at March 31, 2021:
|
|
|
|
Warrants
outstanding
|
|
|
Warrants
exercisable
|
|
|
Exercise price
|
|
|
No. of shares
|
|
|
Weighted
average
remaining
years
|
|
|
Weighted
average
exercise
price
|
|
|
No. of shares
|
|
|
Weighted
average
exercise
price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.000675
|
|
|
|
326,286,847
|
|
|
|
4.28
|
|
|
|
|
|
|
|
326,286,847
|
|
|
|
|
|
|
$0.03000
|
|
|
|
3,703,700
|
|
|
|
0.04
|
|
|
|
|
|
|
|
3,703,700
|
|
|
|
|
|
|
$0.00150
|
|
|
|
66,666,666
|
|
|
|
437
|
|
|
|
|
|
|
|
66,666,666
|
|
|
|
|
|
|
$0.00205
|
|
|
|
477,575,761
|
|
|
|
4.73
|
|
|
|
|
|
|
|
477,575,761
|
|
|
|
|
|
|
$0.12
|
|
|
|
52,237,500
|
|
|
|
0.64
|
|
|
|
|
|
|
|
52,237,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
926,470,474
|
|
|
|
4.30
|
|
|
$
|
0.0082883
|
|
|
|
926,470,474
|
|
|
$
|
0.0082883
|
|
All
of the warrants outstanding as of March 31, 2021 are vested. The warrants outstanding as of March 31, 2021 have an intrinsic value of
$3,227,478.
Our
board of directors adopted the Greenstone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our long-term
growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder value and
contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons for positions
of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance upon exercise of options
granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors and those of our subsidiaries;
provided that only our employees and those of our subsidiaries may receive incentive stock options under the Plan. We have
no issued options at March 31, 2021 under the Plan.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The
Company has two reportable operating segments:
|
|
a.
|
Rental income
from the property owned by CCH subsidiary located at 3571 Muskoka Road, #169, Bala, on which the operations of the Canadian Rehab
Clinic were located prior to disposal on February 14, 2017 and subsequently leased to the purchasers of the business of the Canadian
Rehab Clinic, for a period of 5 years renewable for a further three five-year periods and with an option to acquire the property
at a fixed price.
|
|
|
b.
|
Rehabilitation
Services provided to customers, these services were provided to customers at our Addiction Recovery Institute of America and Seastone
of Delray operations.
|
The
segment operating results of the reportable segments for the three months ended March 31, 2021 is disclosed as follows:
|
|
|
Three months ended March 31, 2021
|
|
|
|
Rental Operations
|
|
In-Patient services
|
|
Total
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
90,793
|
|
|
$
|
—
|
|
|
$
|
90,793
|
|
|
Operating expenditure
|
|
|
(32,849
|
)
|
|
|
(19,167
|
)
|
|
|
(52,016
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
57,944
|
|
|
|
(19,167
|
)
|
|
|
38,777
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on debt conversion
|
|
|
—
|
|
|
|
(1,106,648
|
)
|
|
|
(1,106,648
|
)
|
|
Penalty on convertible notes
|
|
|
—
|
|
|
|
(9,240
|
)
|
|
|
(9,240
|
)
|
|
Fair value of warrants granted
|
|
|
|
|
|
|
(976,788
|
)
|
|
|
(976,788
|
)
|
|
Fair value of warrants exercised
|
|
|
|
|
|
|
(90,000
|
)
|
|
|
(90,000
|
)
|
|
Interest expense
|
|
|
(59,745
|
)
|
|
|
(77,932
|
)
|
|
|
(137,677
|
)
|
|
Amortization of debt discount
|
|
|
—
|
|
|
|
(502,677
|
)
|
|
|
(502,677
|
)
|
|
Change in fair value of derivative liability
|
|
|
—
|
|
|
|
495,589
|
|
|
|
495,589
|
|
|
Foreign exchange movements
|
|
|
(18,695
|
)
|
|
|
(60,797
|
)
|
|
|
(79,492
|
)
|
|
Net loss before taxation
|
|
|
(20,496
|
)
|
|
|
(2,347,660
|
)
|
|
|
(2,368,156
|
)
|
|
Taxation
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Net loss
|
|
$
|
(20,496
|
)
|
|
$
|
(2,347,660
|
)
|
|
$
|
(2,368,156
|
)
|
The
operating assets and liabilities of the reportable segments as of March 31, 2021 is as follows:
|
|
|
March 31, 2021
|
|
|
|
Rental Operations
|
|
In-Patient services
|
|
Total
|
|
|
|
|
|
|
|
|
|
Purchase of fixed assets
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
4,580
|
|
|
|
1,196,939
|
|
|
|
1,201,519
|
|
|
Non-current assets
|
|
|
2,885,861
|
|
|
|
5,157
|
|
|
|
2,891,018
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
(1,484,968
|
)
|
|
|
(12,388,857
|
)
|
|
|
(13,873,825
|
)
|
|
Non-current liabilities
|
|
|
(4,645,209
|
)
|
|
|
—
|
|
|
|
(4,645,209
|
)
|
|
Mandatory redeemable preferred shares
|
|
|
—
|
|
|
|
(400,000
|
)
|
|
|
(400,000
|
)
|
|
Intercompany balances
|
|
|
1,330,423
|
|
|
|
(1,330,423
|
)
|
|
|
—
|
|
|
Net liability position
|
|
$
|
(1,909,313
|
)
|
|
$
|
(12,917,184
|
)
|
|
$
|
(14,826,497
|
)
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
16.
|
Segment information (continued)
|
The
segment operating results of the reportable segments for the three months ended March 31, 2020 is disclosed as follows:
|
|
|
Three months
ended March 31, 2020
|
|
|
|
Rental Operations
|
|
In-Patient
services
|
|
Total
|
|
Revenue
|
|
$
|
83,542
|
|
|
$
|
-
|
|
|
$
|
83,542
|
|
|
Operating expenditure
|
|
|
30,300
|
|
|
|
143,849
|
|
|
|
174,149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
53,242
|
|
|
|
(143,849
|
)
|
|
|
(90,607
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on conversion of convertible
notes
|
|
|
-
|
|
|
|
(286,343
|
)
|
|
|
(286,343
|
)
|
|
Exercise of warrants
|
|
|
-
|
|
|
|
(92,952
|
)
|
|
|
(92,952
|
)
|
|
Interest income
|
|
|
-
|
|
|
|
60
|
|
|
|
60
|
|
|
Interest expense
|
|
|
(61,398
|
)
|
|
|
(132,524
|
)
|
|
|
(193,922
|
)
|
|
Amortization of debt discount
|
|
|
-
|
|
|
|
(403,677
|
)
|
|
|
(403,677
|
)
|
|
Change in fair value of
derivative liability
|
|
|
-
|
|
|
|
(9,754,896
|
)
|
|
|
(9,754,896
|
)
|
|
Foreign
exchange movements
|
|
|
71,619
|
|
|
|
412,432
|
|
|
|
484,051
|
|
|
Net income (loss) before taxation
|
|
|
63,463
|
|
|
|
(10,401,749
|
)
|
|
|
(10,338,286
|
)
|
|
Taxation
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
Net
income (loss)
|
|
$
|
63,463
|
|
|
$
|
(10,401,749
|
)
|
|
$
|
(10,338,286
|
)
|
The
operating assets and liabilities of the reportable segments as of March 31, 2020 is as follows:
|
|
|
March
31, 2020
|
|
|
|
Rental
Operations
|
|
In-Patient
services
|
|
Total
|
|
|
|
|
|
|
|
|
|
Purchase of
fixed assets
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
2,883
|
|
|
|
208,793
|
|
|
|
211,676
|
|
|
Non-current assets
|
|
|
2,677,198
|
|
|
|
—
|
|
|
|
2,677,198
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
(1,149,279
|
)
|
|
|
(27,237,487
|
)
|
|
|
(28,386,766
|
)
|
|
Non-current liabilities
|
|
|
(3,526,779
|
)
|
|
|
(730,235
|
)
|
|
|
(4,257,014
|
)
|
|
Intercompany balances
|
|
|
(704,122
|
)
|
|
|
704,122
|
|
|
|
—
|
|
|
Net liability position
|
|
|
(2,700,099
|
)
|
|
|
(27,054,807
|
)
|
|
|
(29,754,906
|
)
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
17.
|
Net (loss) income per common
share
|
For
the three months ended March 31, 2021 and 2020, the following options, warrants and convertible securities were excluded from the computation
of diluted net loss per share as the results would have been anti-dilutive.
|
|
|
|
|
|
|
Three months ended
March 31,
2021
|
|
Three months ended
March 31,
2020
|
|
|
|
|
|
|
|
Warrants to purchase shares of common stock
|
|
|
926,470,474
|
|
|
|
154,455,397,549
|
|
|
Convertible notes
|
|
|
662,500,729
|
|
|
|
48,756,889,839
|
|
|
|
|
|
1,588,971,203
|
|
|
|
203,212,287,388
|
|
|
18.
|
Commitments and contingencies
|
|
|
a.
|
Contingency related to outstanding
penalties
|
The
Company has provided for potential US penalties of $250,000 due to non-compliance with the filing of certain required returns. The actual
liability may be higher due to interest and penalties assessed by these taxing authorities.
The
company has a mortgage loans as disclosed in note 10 above. The future commitment under this loan is as follows:
|
|
|
Amount
|
|
Within the next twelve months
|
|
|
118,538
|
|
|
Thereafter
|
|
|
3,865,866
|
|
|
Total
|
|
$
|
3,984,404
|
|
The
Company has principal and interest payment commitments under the Convertible notes disclosed under Note 9 above. Conversion of these
notes are at the option of the investor, if not converted these notes may need to be repaid.
From
time to time, the Company and its subsidiaries enter into legal disputes in the ordinary course of business. The Company believes there
are no material legal or administrative matters pending that are likely to have, individually or in the aggregate, a material adverse
effect on its business or results of operations.
On
April 30, 2021 the Company was given a conversion notice of three payments of $30,800 due on April 30, 2021 under the Labrys note entered
into on November 30, 2020 in the aggregate principal amount of $275,000 and 100,000,000 restricted shares were issued. The Company still
has seven more payments of 30,800 due under the note.
On May
10, 2021, the Company closed on a new financing with Labrys for a $550,000 convertible note including a 10% OID for net proceeds of
$500,000. The note bears interest at 10% per annum and has a fixed conversion price of $0.005 per share subject to adjustments should
other new financings be done at more favorable terms. The note is due 12 months from the issuance date. The funding included a five year
warrant for 91,666,666 shares at a conversion price of $0.006 per share.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
19.
|
Subsequent events (continued)
|
On
May 10, 2021, the Company prepaid the note entered into on October 29, 2020 with First Fire Global Opportunities Fund, LLC in the aggregate
principal amount of $137,500. The note was repaid in its entirety.
On
May 12, warrants issued under the note in the amount 50,505,051 shares were exercised on a cashless basis, resulting in the issuance
of 42,353,038 common shares.
On
April 30, 2021 the Company prepaid the note issued on October 29, 2020, to Geneva Roth Remark Holdings, Inc., in the aggregate principal
amount of $88,000. The note has been repaid in its entirety.
On May
10, 2021 the Company prepaid the note issued August 13, 2020, to Auctus Fund LLC, in the aggregate principal amount of $100,000. The
note has been repaid and retired.
On
May 3, 2021, a Company subsidiary Addiction Recovery Institute of America LLC closed on a second PPP loan through Lendistry for net proceeds
of $157,367.
The
Company intends to continue its operations at a new location in west Palm Beach. A Letter of Intent ("LOI") was signed on February
7, 2020, with a third party that has a property lease and a pending license at its new location. The Company originally anticipated recommencing
operations in February 2020, however it has been adversely affected by the COVID-19 pandemic. The LOI requires the Company to provide
a working capital loan of up to $500,000, the Company has loaned $1,026,669 as of March 31, 2021. The Company is expected to
close on the acquisition during the second quarter.